Treatment and Prevention of Bleeding in Adult Hemophilia A Patients with Inhibitor - Economic Analysis

• Autorzy: Wiesław Jędrzejczak , Michał Jachimowicz , Anna Olszyńska
• Języki publikacji: EN

Abstrakty

EN

Hemophilia A is caused by an absence or deficiency of coagulation factor VIII. Patients with hemophilia may experience recurrent spontaneous hemarthroses or internal bleeding. Following the treatment with factor VIII concentrates, patients with hemophilia A may develop alloantibodies to factor VIII, evidence of which is critical to diagnose hemophilia with inhibitor. The primary goal of treatment in patients with hemophilia with inhibitor is a durable inhibitor elimination and the interim goal is to stop the bleeding. The aim of this paper is to compare the effectiveness and costs of on-demand therapy and prophylaxis in patients with hemophilia A with or without inhibitor. We conducted a review of studies. The outcomes of the studies included in the review suggested that the difference in annual bleeding rate (ABR) between prophylaxis and on-demand therapy is less pronounced in patients with inhibitor. Furthermore, one study found no statistically significant difference in ABR between prophylaxis and on-demand therapy in patients aged ≥ 40, although the consumption of coagulation factor was significantly higher in the prophylaxis group. Treatment of patients with hemophilia A is associated with high costs of coagulation factor concentrates and frequent, stressful and painful injections. Therefore, while considering the introduction of prophylaxis in adult patients, it appears advisable to select groups of patients depending on the frequency of bleeding episodes and to determine adequate treatment strategy(original abstract)

Słowa kluczowe

EN

Illness; Medical treatment

PL

Choroby; Leczenie

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2016
• Numer: nr 1
• Strony: 75--81

Twórcy

autor

Wiesław Jędrzejczak

• Medical University of Warsaw, Warsaw, Poland

autor

Michał Jachimowicz

• MAHTA, Warsaw, Poland

autor

Anna Olszyńska

• MAHTA, Warsaw, Poland

Bibliografia

• Windyga J. Hemofilie - postępy w diagnostyce i leczeniu. Acta Haematologica Polonica 2010; 41 (2): 183-199
• Ministry of Health. Narodowy Program Leczenia Chorych na Hemofilię i Pokrewne Skazy Krwotoczne na lata 2012-2018. 2012; Available from: http://www.mz.gov.pl/zdrowie-i-profilaktyka/krwiodawstwo/program-zdrowotny-narodowy-program-leczenia-chorych-na-hemofilie-i-pokrewne-skazy-krwotoczne-na-lata-2012-2018/; [Accessed: 11.06.2016]
• Windyga J, Chojnowski K, Klukowska A. et al. Polskie zalecenia postępowania we wrodzonych skazach krwotocznych na tle niedoboru czynników krzepnięcia. Acta Haematologica Polonica 2008; 39 (3): 565-579
• Jamrozik M, Krawczyk-Kuliś M, Kyrcz-Krzemień S. et al. Rola profilaktyki okresowej w leczeniu ciężkiej i umiarkowanej hemofilii. Katedra i Klinika Hematologii i Transplantacji Szpiku Śląskiego Uniwersytetu Medycznego 2015; 1-12
• Blanchette VP. Prophylaxis in the haemophilia population. Haemophilia 2010; 16 (5): 181-188
• Leissinger C, Gringeri A, Antmen B, et al. Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. NEJM 2011; 365: 1684-92
• Jackson SC, Yang M, Minuk L, et al. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematology 2015; 15 (4): 1-8
• Narodowe Centrum Krwi, Wyniki raportu za 2013 rok sporządzone w oparciu o dane przesłane przez wojewódzkich koordynatorów ds. leczenia hemofilii i pokrewnych skaz krwotocznych. 2013 [Accessed: 11.06.2016]. Available from: http://www.nck.gov.pl/wp-content/uploads/2014/06/Wyniki-raportu-Jednostki-Koordynuj%C4%85cej-za-2013-rok.pdf
• Goszczyńska K, Wrona W, Niewada M. Porównanie kosztów terapii lekami omijającymi inhibitor w leczeniu łagodnych i umiarkowanych krwawień u chorych z hemofilią wrodzoną powikłaną inhibitorem w Polsce. Journal of Transfusion Medicine 2011; 4 (3): 115-122
• Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors. Seminars in Thrombosis & Hemostasis 2013; 39 (7): 772-778
• European Medicines Agency, Charakterystyka Produktu Leczniczego NovoSeven® 2016. [Accessed: 11.06.2016]. Available from: http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf
• Baxter, Charakterystyka Produktu Leczniczego Feiba® 2010. [Accessed: 11.06.2016]. Available from: http://www.baxter.com.pl/downloads/charakterystyki/BioScience/Feiba_NF.pdf
• Lyseng-Williamson KA, Plosker GL. Recombinant Factor VIIa (Eptacog Alfa). A Pharmacoeconomic Review of its Use in Haemophilia in Patients with Inhibitors to Clotting Factors VIII or IX. Pharmacoeconomics 2007; 25 (12): 1007-1029
• Zakład Zamówień Publicznych przy Ministrze Zdrowia, Zużycie i wydatki na preparat rFVIIa stosowany w leczeniu chorych na hemofilię powikłaną inhibitorem na podstawie przetargów 2013 [Accessed: 11.06.2016]. Available from: http://www.zzpprzymz.pl/ogloszenia-o-przetargach.php
• Dundar S, Zülfikar B, Kavakli K, et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005; 8: 45-54
• Hart WM. An economic evaluation of NovoSeven in the man agement of haemophilia patients with inhibitors in Slovakia [abstract no. POD1, poster presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Resear]. Value Health 2002; 5 (6): 576- 7
• Odeyemi AO, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated pro- thrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002; 5: 119-33
• Ozelo MC, Villaca PR, De Almeida JO, et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007; 13 (5): 462-9
• Plyush O, Kopylov K, Zozulya N, et al. A cost evaluation of treament alternatives in mild-to-moderate bleeding episodes in haemeophilia patients with inhibitors in Russia [in Russian]. Paediatr Haematol Oncol Immunopathol 2006; 5 (3): 16-22
• Yoo SK, Yong LS, Kyu PS, et al. Pharmaco-economic evaluation of treatment alternatives for mild to moderate bleeding episodes in patients with haemophilia with inhibitors in Korea [abstract no. P-W-158 plus poster]. 21st Congress of the Inter- national Society on Thrombosis and Haemostasis 2007
• Estymator, Wyniki badań ankietowych na temat: waga i nadwaga Polaków, wrzesień 2006, http://www.estymator.com.pl/
• National Hemophilia Foundation, Masac Recommendation Regarding Prophylaxis With Bypassing Agents In Patients With Hemophilia And High Titer Inhibitors 2013. [Accessed: 11.06.2016]. Available from: https://www.hemophilia.org/sites/default/files/document/files/masac220.pdf
• Negrier C, Voisin S, Baghaei F et al. Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis 2016; 27 (5): 551-6
• Matza L, Cong Z, Chung K. et al. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases. Patient Preference and Adherence 2013; 7: 855-865
• Forsyth A, Witkop M, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study, Patient Prefer Adherence. 2015; 9: 1549-1560

Identyfikatory

DOI

10.7365/JHPOR.2016.1.12